Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan.

Murad JP, Espinosa EV, Ting HJ, Khasawneh FT.

J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):308-14. doi: 10.1177/1074248411425491. Epub 2011 Nov 28.

PMID:
22123197
2.

Glybenclamide: an antidiabetic with in vivo antithrombotic activity.

Ting HJ, Khasawneh FT.

Eur J Pharmacol. 2010 Dec 15;649(1-3):249-54. doi: 10.1016/j.ejphar.2010.09.009. Epub 2010 Sep 19.

PMID:
20858477
3.

An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.

Jin YR, Cho MR, Lee KS, Lee JJ, Lim Y, Han XH, Oh KW, Hong JT, Yoo HS, Yun YP.

Basic Clin Pharmacol Toxicol. 2005 Sep;97(3):162-7.

4.
5.

Effect of losartan on human platelet activation.

Guerra-Cuesta JI, Montón M, Rodríguez-Feo JA, Jiménez AM, González-Fernández F, Rico LA, García R, Gómez J, Farré J, Casado S, López-Farré A.

J Hypertens. 1999 Mar;17(3):447-52.

PMID:
10100084
6.

Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.

Lee JJ, Jin YR, Lim Y, Hong JT, Kim TJ, Chung JH, Yun YP.

Vascul Pharmacol. 2006 Sep;45(3):148-53. Epub 2006 Jun 23.

PMID:
16916624
8.

Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.

Jiménez AM, Montón M, García R, Núñez A, Gómez J, Rico L, García-Colis E, de Miguel LS, Arriero MM, Cabestrero F, Farré J, Casado S, López-Farré A.

J Cardiovasc Pharmacol. 2001 Apr;37(4):406-12.

PMID:
11300653
9.

Angiotensin II AT(1) receptor antagonists and platelet activation.

López-Farré A, Sánchez de Miguel L, Montón M, Jiménez A, Lopez-Bloya A, Gómez J, Núñez A, Rico L, Casado S.

Nephrol Dial Transplant. 2001;16 Suppl 1:45-9. Review.

PMID:
11369820
10.

BF066, a novel dual target antiplatelet agent without significant bleeding.

Pan C, Wei X, Ye J, Liu G, Zhang S, Zhang Y, Du H, Ding Z.

PLoS One. 2012;7(7):e40451. doi: 10.1371/journal.pone.0040451. Epub 2012 Jul 16.

11.

Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.

Dogné JM, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L, Rolin S, Ghuysen A, Segers P, Lambermont B, Masereel B, Pirotte B.

J Pharmacol Exp Ther. 2004 May;309(2):498-505. Epub 2004 Jan 23.

12.

A novel antibody targeting the ligand binding domain of the thromboxane A₂ receptor exhibits antithrombotic properties in vivo.

Murad JP, Espinosa EV, Ting HJ, McClure D, Khasawneh FT.

Biochem Biophys Res Commun. 2012 May 11;421(3):456-61. doi: 10.1016/j.bbrc.2012.04.011. Epub 2012 Apr 7.

PMID:
22503974
13.

Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers.

Sato Y, Fujii S, Imagawa S, Ohmura K, Ohmura Y, Andoh Y, Dong J, Ishimori N, Furumoto T, Tsutsui H.

J Atheroscler Thromb. 2007 Feb;14(1):31-5.

14.

Antiplatelet effect of phloroglucinol is related to inhibition of cyclooxygenase, reactive oxygen species, ERK/p38 signaling and thromboxane A2 production.

Chang MC, Chang HH, Chan CP, Chou HY, Chang BE, Yeung SY, Wang TM, Jeng JH.

Toxicol Appl Pharmacol. 2012 Sep 15;263(3):287-95. doi: 10.1016/j.taap.2012.06.021. Epub 2012 Jul 9.

PMID:
22789837
15.

Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid inhibits platelet activation and thrombosis via inhibition of thromboxane A2 signaling and phosphodiesterase.

Zhang SH, Zhang Y, Shen J, Zhang S, Chen L, Gu J, Mruk JS, Cheng G, Zhu L, Kunapuli SP, Ding Z.

J Thromb Haemost. 2013 Oct;11(10):1855-66. doi: 10.1111/jth.12362.

17.

Repurposing an old drug for a new use: glybenclamide exerts antiplatelet activity by interacting with the thromboxane A(2) receptor.

Ting HJ, Murray WJ, Khasawneh FT.

Acta Pharmacol Sin. 2010 Feb;31(2):150-9. doi: 10.1038/aps.2009.195.

18.
19.

Antagonistic effects of losartan on thromboxane A2-receptors in human isolated gastroepiploic artery and saphenous vein.

Tripodi F, Stanke-Labesque F, Devillier P, Chavanon O, Sessa C, Bessard G.

J Cardiovasc Pharmacol. 1999 Nov;34(5):734-40.

PMID:
10547091
20.

Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.

Karnicki K, Leadley RJ Jr, Baxi S, Peterson T, Wysokinski W, McBane RD 2nd.

Thromb Haemost. 2008 Apr;99(4):759-66. doi: 10.1160/TH07-09-0576.

PMID:
18392334

Supplemental Content

Support Center